In commercial poultry and swine drinking-water medication lines, the liquid extract is introduced after the final filtration stage but before the proportioning pump so that recirculation shear and residence time in the distribution system remain below the point at which saponin-stabilised foam becomes entrained in solenoid-driven dosing valves. The extract is transferred from 316L stainless-steel IBC storage at 15–25°C using a positive-displacement pump; centrifugal transfer is avoided because dissolved saponins lower surface tension sufficiently to generate stable foam under impeller cavitation. For aqueous oral solution preparation, the vehicle is prepared as deionised water adjusted to 4.0–5.5 with citric acid monohydrate or sodium citrate dihydrate, followed by addition of potassium sorbate at 0.1–0.2% w/v where a preservative is required. The liquid extract is added under low-rpm bottom-entry agitation at 60–120 rpm with vacuum deaeration at −0.05 to −0.08 MPa to collapse entrained air. The final solution is passed through a 50–100 µm bag filter before filling into HDPE or amber PET containers. Because saponins are susceptible to acid-catalysed hydrolysis, pH is re-checked after extract addition and corrected within the same buffer range; long-term storage is limited to ≤25°C with light protection. Viscosity is typically reduced by the aqueous vehicle, and the target solution viscosity of ≤20 mPa·s at 20°C is measured using a Brookfield LV viscometer at spindle speed 60 rpm to confirm compatibility with 1:50 to 1:200 inline proportioning pumps. Analytical release includes total saponin content by HPLC using a method validated according to VICH GL1 and ICH Q2(R1), ethanol content where relevant, microbial limits, and pH. In drinking-water applications the diluted solution is incompatible with strong oxidising disinfectants such as sodium hypochlorite or chlorine dioxide; administration lines should be flushed before and after dosing to prevent precipitation of saponin-metal complexes in hard water above 250 mg/L CaCO₃ equivalent. Stability is evaluated under VICH GL3 conditions in orientation studies at 25°C/60% RH and 40°C/75% RH, with saponin retention, pH drift, and preservative depletion as primary failure indicators. Terminal product is an oral drench or drinking-water concentrate for respiratory tract support in swine, broilers, layers, and calves, with dosing calibrated according to body weight and daily water intake variability, not to a fixed concentration alone.

Where Feed Intake Variability Drives Premix Homogeneity Limits

Medicated premix manufacture with this extract is governed less by the chemical stability of saponins than by the uniform distribution of a relatively small mass of viscous liquid across a large mass of dry feed carrier. The liquid extract is first warmed to 30–35°C in a jacketed vessel to reduce viscosity before being metered through an atomising nozzle into a ribbon, paddle, or twin-shaft paddle mixer containing a carrier blend of ground corn cob, wheat middlings, calcium carbonate, and precipitated silica. Compressed air for nozzle atomisation is maintained at 4–6 bar and supplied through a filter-regulator meeting ISO 8573-1:2010 solid and water class 2 to avoid introducing fine particulates or moisture into the mixing zone. The mixer working volume is held at the manufacturer-defined fill level, and the liquid addition rate is adjusted so that the wetted carrier does not exceed 12% final moisture as determined by loss-on-drying at 103°C to a constant mass according to an AOAC moisture method; higher residual moisture increases the risk of mould growth and clumping during bag storage. Homogeneity is assessed by sampling from at least 10–20 locations across the discharged batch using a riffling divider and determining total saponin content or a tracer marker in each sample. Acceptable premix homologue limits are normally expressed as a coefficient of variation of ≤5% for ribbon and twin-shaft mixers and ≤7% for single-shaft paddle mixers, measured according to sampling plans consistent with ISO 6497:2002. The process window is narrow for this material because excessive atomisation pressure produces fine mist that adheres to mixer walls and seals rather than the carrier, while insufficient pressure discharges large droplets that form saponin-rich agglomerates. After mixing, the premix is discharged into paper sacks with a PE liner and stored in ventilated areas at ≤25°C and relative humidity under 60% to limit moisture migration. The terminal product is intended for farm mixing into complete feed at a usage rate dictated by the final dosing scheme; the primary in-use risk is segregation during screw conveyor transfer, so bulk density and particle size of the premix are controlled to remain within ±10% of the target feed carrier specification.

Wet Granulation Windows for Saponin-Rich Polygala Extract in Companion Animal Tablets

Tablet manufacture from a liquid extract does not begin with direct compression; the extract must first be converted into a granulated solid mass in which the saponin fraction is dispersed within a moisture-tolerant absorbent matrix. The liquid extract is pre-blended with microcrystalline cellulose and colloidal silicon dioxide in a high-shear granulator at impeller speed 150–300 rpm for 30–90 seconds before adding the extract as the granulating fluid itself or as a water-extract mixture. Ethanol present in the incoming extract modifies the granulation endpoint: high ethanol content reduces surface tension and produces a drier-feeling mass that can rapidly overwet when additional water is introduced, while low ethanol content increases viscosity and extends mixing time. The granulation is complete when the power consumption curve reaches a plateau and the wet mass passes a 1.0–2.0 mm screen without smearing. Drying is performed in a fluid-bed dryer with inlet air temperature limited to 50–60°C and product temperature maintained below 40°C to avoid saponin hydrolysis and colour darkening. Dried granules are milled through an oscillating granulator fitted with a 0.8 mm screen and blended with crospovidone at 2–5% w/w, microcrystalline cellulose diluent, and magnesium stearate at 0.5–1.0% w/w. Compression is carried out on a rotary tablet press with a compression force range of 12–20 kN for flat-faced bevel-edged punches; target hardness is 50–80 N and friability is required to be ≤1.0% after 100 revolutions in a Roche friabilator according to USP <1216>. Disintegration time is held to ≤15 minutes in water at 37°C using USP <701> apparatus, and content uniformity is evaluated by USP <905> with an acceptance value of ≤15.0. Because saponin-rich extracts are hygroscopic and bitter, tablets are coated with an HPMC-based film at 3–5% weight gain in a side-vented coating pan with inlet air temperature 50–65°C and pan speed 6–12 rpm. The coated tablets are packed in alu-alu blister formats to limit moisture ingress during storage at 25°C/60% RH. Operational boundaries are defined by the granulation water content and the drying rate: over-drying below 2% LOD produces friable granule edges and tablet capping, while residual moisture above 4% causes picking and sticking during compression and increases disintegration variability. Batch-to-batch variation in extract dry matter therefore requires adjustment of granulating fluid volume and drying time rather than fixed equipment settings. Published data for this specific Polygala liquid extract configuration in veterinary tablets is limited, so development batches use placebo granulations with a saponin-free botanical extract surrogate to map the water activity and compression profile before active extract is introduced.

When Polygala Extract Is Considered for Injectable Dosage Forms

Injectable administration of this extract is constrained primarily by the haemolytic potential of triterpenoid saponins and the need to achieve acceptable endotoxin and particulate control without terminal sterilisation. If a parenteral formulation is evaluated, the extract must be processed as a purified active ingredient rather than a crude oral-grade liquid because the saponin fraction can disrupt erythrocyte membranes in vitro; target-species haemolysis screening on washed erythrocytes is required, and a conservative development threshold of ≤5% haemolysis in 1 hour at 37°C is typically applied, although no harmonised veterinary acceptance limit exists and published data for this specific configuration is limited. The formulation vehicle is prepared as Water for Injection in a stainless-steel 316L mixing vessel, with osmolality adjusted to 280–320 mOsm/kg using sodium chloride and pH adjusted to 6.0–7.4 with dilute hydrochloric acid or sodium hydroxide. Acidic pH values below 5.5 are avoided because saponin hydrolysis accelerates under acid conditions, while alkaline pH can promote oxidative discolouration. The extract is added as a filterable liquid after pre-filtration through a 0.45 µm membrane, and the final solution is sterile-filtered through a 0.22 µm PVDF or low-binding PES membrane. Membrane compatibility is evaluated by measuring saponin recovery and membrane flux because surface-active saponins can foul hydrophobic membranes and reduce throughput; filter integrity testing is performed according to ASTM F838-20 before and after filtration. Aseptic filling is conducted in an ISO 14644-1:2015 Grade A critical zone with Grade B surrounding environment following EU GMP Annex 1 requirements, because the saponin fraction is heat-sensitive and terminal steam sterilisation at 121°C is not a viable option. Endotoxin control is addressed through depyrogenation of the starting extract and vehicle by ultrafiltration or anion-exchange adsorption, with final endotoxin monitored by USP <85> using target-species dose-based limits. The primary operational boundary is the haemolytic threshold, which may vary by species, erythrocyte source, and saponin composition; injectable use is therefore restricted to development routes where a clear therapeutic margin can be demonstrated. Incompatibilities include polyvalent metal ions that may precipitate acidic saponin fractions and strong oxidising preservatives that destabilise the extract. Any injectable formula must also comply with residual solvent limits under VICH GL18 and sterility testing under USP <71>, with process hold time kept below the validated maximum to reduce bioburden regrowth risk.

Because hard gelatin capsule filling requires free-flowing powders with controlled water activity, the liquid extract is first converted to an adsorbed solid matrix rather than filled directly. The extract is mixed with microcrystalline cellulose and fumed silica in a planetary mixer at 30–60 rpm for 10–20 minutes until a free-flowing powder is obtained; the sorbent ratio is determined by the oil-adsorption capacity of the selected silica grade and the dry matter content of the extract batch. The adsorbed mass is passed through a 0.5 mm conical mill to break agglomerates, then blended with magnesium stearate at 0.5% w/w for 3–5 minutes to avoid over-lubrication. Powder flow is assessed by Carr index and Hausner ratio using USP <1174> methods, with a target Carr index of ≤25 and a Hausner ratio of ≤1.25 for dosator or tamping-pin capsule filling machines. The blend is filled into size 1 or 2 hard gelatin or HPMC capsules under controlled room conditions of 20–25°C and 35–45% RH to prevent shell brittleness and static charge build-up. Fill weight variation is controlled to RSD ≤3.0% across a production run and content uniformity is confirmed by USP <905>. Disintegration is tested in water at 37°C with a limit of ≤15 minutes using USP <701>. Gelatin shell cross-linking is a recognised risk if residual aldehydes are present in the extract or formed during storage; where this occurs, HPMC capsules are preferred because they do not undergo aldehyde-mediated cross-linking. The terminal product is a companion animal oral capsule for expectorant or upper respiratory support, packed in HDPE bottles with desiccant canisters to maintain internal relative humidity below 40%. Stability is assigned only after confirming that capsule shell moisture content, saponin content, and dissolution behaviour remain within specification under VICH GL3 intermediate conditions of 30°C/65% RH for zones where prolonged ambient storage is expected.

Granule Carrier Systems and Saponin Leaching Behaviour During Dissolution

Granule formation from the liquid extract is carried out by fluid-bed top-spray deposition onto inert carrier particles such as sucrose spheres or lactose monohydrate granules, producing a saponin-dispersed layer that controls both dose accuracy and release rate. The extract is diluted with purified water to a viscosity suitable for atomisation, typically below 50 mPa·s at 25°C, and sprayed through a two-fluid nozzle at atomisation pressure 1.5–3.0 bar and inlet air temperature 45–55°C. Product temperature is kept at 35–40°C by adjusting spray rate and air flow, because higher bed temperatures accelerate surface drying before droplet spreading and produce uneven saponin distribution. The sprayed granules are dried to a loss-on-drying value of ≤3.0% and sieved to retain the 0.5–1.0 mm fraction for final packaging. Bulk density is controlled between 0.5 g/mL and 0.7 g/mL to maintain consistent volumetric dosing in sachet lines. Dissolution testing is performed in 900 mL of phosphate buffer at pH 6.8 and 37°C using USP <711> apparatus II with paddle speed 50 rpm; saponin release is measured at 15 min, 30 min, and 45 min to characterise the diffusion-controlled phase from the carrier surface. A rapid initial release is expected from the surface-deposited layer, while the later phase reflects diffusion from carrier pores; a minimum plateau of ≥80% released within 30 minutes is applied only where the granule is intended for immediate-release oral administration to piglets or calves. The most important processing limitation is the glass transition of the spray-dried saponin-maltodextrin layer: if the product temperature drifts above 40°C, the deposited layer can become tacky and initiate bed collapse, while temperatures below 30°C slow drying and increase agglomeration. The terminal product is packed in polypropylene sachets with low moisture vapour transmission rate film, and the granule bed is protected from humidity above 60% RH during storage and handling.

For drinking-water soluble powder applications, the extract is spray-dried rather than simply diluted, because a dry free-flowing powder is required for farm-level reconstitution under variable water quality and mixing conditions. The liquid extract is blended with a carrier such as maltodextrin or lactose monohydrate to a feed solids content of 15–25% w/w and homogenised before spray drying. Inlet air temperature is set at 140–160°C and outlet air temperature is controlled at 60–70°C so that the drying chamber provides rapid moisture removal without exposing the dried particle surface to excessive heat for more than a few seconds. The resulting powder is combined with fumed silica at 1–2% w/w as a flow aid and passed through a 0.5 mm screen before filling into laminated foil pouches. Final powder moisture is controlled to ≤5.0% by loss-on-drying at 105°C, and solubility at 20°C is tested by adding 0.5 g powder to 100 mL of water with gentle stirring for 5 minutes; the formation of haze or sediment is recorded as an incompatibility indicator, particularly in hard water where saponin-metal interactions can reduce solution clarity. The terminal powder is administered by inline dosing pump or stock solution preparation for broiler, layer, and swine drinking-water lines. The primary storage boundary is moisture ingress: once the pouch is opened, the remaining powder must be protected from ambient humidity above 60% RH to prevent caking and loss of flowability. The product is not suitable for direct mixing into dry feed without prior reconstitution because the fine particle size and low bulk density of the powder create segregation risk in conventional feed mixers.